May 7, 2026 • 36 mins
We explore why a shingles vaccine is showing surprising links to lower dementia risk and slower biological aging, then we stress-test those headlines with the mechanics of immunology and the limits of observational research. We end with a practical “bonus philosophy”: follow vaccine guidelines to prevent shingles pain now, and keep your brain protected with proven daily habits while the trials catch up.
• how varicella zoster hides in nerve ganglia for decades and reactivates with age-related immune decline
• why shingles can cause severe neuropathic pain and long-lasting postherpetic neuralgia
• how a Wales policy cutoff creates a near-randomized “bouncer” study design
• the reported 20% lower dementia risk signal and why it grabs attention
• why doctors urge caution about correlation versus causation and residual confounding
• Zostavax versus Shingrix differences and why vaccine mechanics matter
• two competing mechanisms: direct immune effects on the brain versus protection from inflammatory shingles trauma
• biological aging markers, epigenetic clocks and transcriptomic aging links to vaccination
• the hypothesis of subclinical viral reactivation driving background inflammation
• CDC shingles vaccine guidance and why we treat cognitive benefits as a bonus
• the proven dementia prevention toolkit: blood pressure, exercise, sleep, diet and social connection
This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.
Never miss an episode—subscribe on your favorite podcast app!
Listen
Watch
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
SPEAKER_01 (00:00):
What if um what if the secret to slowing down your
biological clock and likeactually fending off dementia
has just been sitting in yourlocal pharmacy this whole time?
SPEAKER_00 (00:09):
Yeah, disguised as a common skin rash vaccine, right?
It's it's the kind of questionthat forces us to completely
rethink how we view preventativemedicine altogether.
SPEAKER_01 (00:17):
Aaron Powell Exactly.
I mean, we are so used to thesehighly targeted treatments like
you take a pill for bloodpressure or you get a cast for a
broken bone.
SPEAKER_00 (00:25):
Aaron Powell Right, very one-to-one solutions.
But the idea that a singlestandard inoculation could
ripple out and uh protect thebrain's architecture years down
the line, that is a massiveparadigm shift.
SPEAKER_01 (00:36):
Aaron Powell And it's not just some abstract
theory anymore, which is wild.
Today our mission on this deepdive is to tear into this
updated February 2026 healthgrades article.
SPEAKER_00 (00:46):
By David Mills, I believe.
SPEAKER_01 (00:47):
Yeah.
Written by David Mills andfact-checked by Jennifer Chisak.
And the title just lays it outperfectly.
Shingles Vaccines and Dementia,promising data, early evidence.
SPEAKER_00 (00:57):
It's a great piece.
SPEAKER_01 (00:58):
It really is.
So we are going to unpack themassive, groundbreaking studies
driving this whole conversation.
But uh we're also going toconfront the intense medical
skepticism that's kind ofpushing back against the hype
right now.
SPEAKER_00 (01:14):
Aaron Powell Because navigating that tension, you
know, the space between aphenomenal statistical
correlation and an actual provenmedical treatment is where the
real understanding happens.
Right.
For anyone listening who is likeactively trying to map out a
long-term strategy for theircognitive health, simply reading
those flashy headlines isn'tenough.
We really need to dissect thewhy and the how.
SPEAKER_01 (01:35):
We have to get into the weeds, look at the cellular
mechanisms, the epidemiologicalblind spots, all of it.
SPEAKER_00 (01:40):
Exactly.
And the fundamental differencesbetween the vaccines themselves,
which is a huge part of thispuzzle.
SPEAKER_01 (01:45):
Aaron Powell Okay, let's unpack this.
SPEAKER_00 (01:46):
Okay.
SPEAKER_01 (01:47):
Because to grasp how a vaccine might protect your
brain, we first have tounderstand the specific enemy it
was built to fight.
And uh the shingles virus is auniquely insidious foe.
SPEAKER_00 (01:58):
Aaron Powell It really is.
We are not talking about a germyou catch from a doorknob, get
sick from for a week, and thenjust clear from your system.
SPEAKER_01 (02:03):
Aaron Powell Not at all.
The story of shingles actuallybegins decades before the rash
ever appears.
It begins with chickenpox.
SPEAKER_00 (02:11):
Right, the varicella zoster virus.
Right.
Or herpes zoster, which is thepathogen responsible for chicken
pox.
SPEAKER_01 (02:16):
Aaron Powell And for the vast majority of adults
alive today, especially thosewho grew up before the varicella
vaccine became, you know, astandard childhood memionation,
an infection was just auniversal rite of passage.
SPEAKER_00 (02:30):
Oh, absolutely.
You got the itchy spots, youstayed home from school, maybe
you even wore oven mitts to stopyourself from scratching, right?
SPEAKER_01 (02:36):
Aaron Powell Yeah, the oatmeal baths.
And eventually your immunesystem mounts a defense, the
spots fade, and you just assumethe battle is over.
You think the virus is gone.
SPEAKER_00 (02:45):
But the virus was not gone.
That is the crucial part.
The varicella zostovirus ishighly adept at evasion.
SPEAKER_01 (02:51):
It's a sneaky one.
SPEAKER_00 (02:52):
Very.
During that initial childhoodinfection, while your immune
system was busy, you know,clearing the virus from your
skin and bloodstream, viralparticles were silently
retreating.
SPEAKER_01 (03:02):
Retreating where?
SPEAKER_00 (03:03):
They travel along your nerve fibers, they move
away from the skin and go deepinto your body's sensory nervous
system.
SPEAKER_01 (03:09):
It's so creepy to think about.
They act as sleeper agents.
They literally slip past theactive war zone and find a
hiding place where the immunesystem just won't hunt them
down.
SPEAKER_00 (03:18):
Specifically, they set up latency in the dorsal
root ganglia and the cranialnerve ganglia.
SPEAKER_01 (03:24):
Which are what exactly?
For the listeners who aren'tneurologists.
SPEAKER_00 (03:27):
Right.
So these are essentiallyclusters of nerve cell bodies
located just outside the spinalcord and at the base of the
brain.
The viral DNA enters these nervecells and exists as what we call
an episome.
SPEAKER_01 (03:39):
An episome.
Okay, I mean, what does thatactually look like in the cell?
SPEAKER_00 (03:42):
Aaron Powell Well, it means it doesn't integrate
directly into your human DNA.
It just sits there, dormant,entirely self-contained.
It completely halts its ownreplication.
SPEAKER_01 (03:52):
So it just sits in the dark for 20, 40, maybe 60
years.
SPEAKER_00 (03:55):
It waits.
And it is kept in check by youradaptive immune system,
specifically a type of whiteblood cell known as a memory T
cell.
SPEAKER_01 (04:03):
Okay, so the T cells are like the prism guards.
SPEAKER_00 (04:05):
That's a great analogy.
These T cells act as permanentguards, constantly patrolling
the ganglia.
If the virus tries to replicateand wake up, the T cells
immediately shut it down beforeyou ever feel a single symptom.
SPEAKER_01 (04:18):
But as we age, we go through this process called
immunosnescence, right?
Our immune system naturallystarts to weaken.
SPEAKER_00 (04:24):
Exactly.
The T cell patrols become lessfrequent, and the individual
cells themselves become lesseffective.
SPEAKER_01 (04:30):
The guards get tired, the perimeter weakens,
and that sleeper agent finallysees its window to strike.
SPEAKER_00 (04:37):
And that is when the virus reactivates.
It begins to multiply inside thenerve ganglion, which causes
severe inflammation.
Then it uses the nerve fiberitself as a highway.
SPEAKER_01 (04:48):
Traveling all the way back up to the surface of
the skin.
SPEAKER_00 (04:50):
Yes, and this causes the characteristic Kringles
rash.
But because the virus isliterally traversing and
damaging the sensory nervetissue along the way, the
defining characteristic ofshingles is profound, agonizing
neuropathic pain.
SPEAKER_01 (05:04):
Yeah, this isn't just a bad itch.
The source text fromHealthGrades cites Dr.
Dun Trin, an internist whotreats this regularly.
SPEAKER_00 (05:10):
He's very clear about the severity.
SPEAKER_01 (05:12):
He really is.
He makes it clear that shinglesis common, it is intensely
painful, and the consequencescompound significantly with age.
Some people develop a conditioncalled posttherpetic neuralgia.
SPEAKER_00 (05:24):
Which is devastating.
That's where the nerve damage isso severe that the burning
stabbing pain persists formonths, sometimes even years
long after the skin has actuallyhealed.
SPEAKER_01 (05:34):
And the sheer scale of the problem is difficult to
overstate.
The CDC statistic highlighted inthe article is pretty sobering.
One in three people in theUnited States will develop
shingles in their lifetime.
SPEAKER_00 (05:45):
One in three.
When a condition impacts a thirdof the entire population, the
medical system has to respondwith a massive intervention.
SPEAKER_01 (05:53):
Which is why the push for shingles vaccination in
older adults is so aggressiveright now.
The goal is to um artificiallyboost those aging T cells,
right?
SPEAKER_00 (06:03):
Exactly.
You're reinforcing the guard andtrying to keep that sleeper
agent locked in the gangliaforever.
SPEAKER_01 (06:08):
And that aggressive public health campaign is
exactly what paved the way forthese wild dementia findings.
SPEAKER_00 (06:14):
Because we are administering millions and
millions of doses of thisvaccine.
SPEAKER_01 (06:18):
Right.
And when you have a data set,that massive modern epidemiology
allows you to look past theprimary goal of the
intervention.
You start to observe secondaryeffects that literally no one
anticipated.
SPEAKER_00 (06:30):
What's fascinating here is how they found this,
which brings us to the WelshBouncer study.
SPEAKER_01 (06:35):
Yes, let's talk about the Welsh Bouncer.
We need to look at this initialstudy led by researchers at
Stanford University, which waspublished in the journal Nature.
SPEAKER_00 (06:43):
They examined the health records of over 280,000
older adults in Wales, ages 71to 88.
SPEAKER_01 (06:50):
And the methodology here is what elevates this from
just like a casual observationto a highly rigorous
epidemiological tool.
They didn't just look at whochose to get a vaccine and who
didn't over a random decade.
SPEAKER_00 (07:03):
No, they zeroed in on a very specific national
vaccination program that wasrolled out in Wales with an
exact starting date.
SPEAKER_01 (07:10):
September 1st, 2013.
SPEAKER_00 (07:12):
Right.
And the government attached anincredibly rigid arbitrary rule
to this rollout.
SPEAKER_01 (07:17):
It's so bureaucratic, but it's brilliant
for science.
If you were 79 years old onSeptember 1st, 2013, you were
eligible to receive the shinglesvaccine.
SPEAKER_00 (07:26):
But if you were 80 years old or older on that exact
date, you were cut off.
No vaccine for you.
SPEAKER_01 (07:33):
So Dr.
Pascal Geldsesser, an assistantprofessor of medicine at
Stanford and the senior authorof subsequent study, pointed out
that this rigid cutoffessentially mimics a randomized
clinical trial.
SPEAKER_00 (07:45):
In statistics, we call this a regression
discontinuity design.
SPEAKER_01 (07:49):
Okay, let's visualize this cutoff like a
bouncer at a club on September1st.
Two people walk up to the door.
They are neighbors.
SPEAKER_00 (07:57):
They eat the same diet, they have the same
baseline cardiovascular health.
SPEAKER_01 (08:00):
Yeah, the exact same socioeconomic status.
But one of them was born onAugust 31st, making them 80
years old.
The other was born on September2nd, making them 79 years old.
SPEAKER_00 (08:10):
So the 79-year-old gets VIP access, they are
granted the intervention, andthe 80-year-old is turned away
at the door.
SPEAKER_01 (08:16):
They're biologically practically identical.
They're separated by days, yetone is suddenly placed in a
vaccinated cohort, and the otheris placed in an unvaccinated
control group.
SPEAKER_00 (08:26):
And this mathematical quirk naturally
filters out the massive muddyingvariables that usually plague
observational research.
SPEAKER_01 (08:33):
Right, because usually we have to worry that
wealthy people were more likelyto buy the vaccine or that super
health conscious people soughtit out.
SPEAKER_00 (08:40):
But here, the sole determining factor was an
arbitrary line drawn in the sandby a health ministry.
SPEAKER_01 (08:46):
It's incredible.
By tracking these two perfectlydivided groups over a seven-year
period, the Stanford researcherswere able to isolate the effect
of the vaccine itself.
SPEAKER_00 (08:57):
And when they cross-referenced that data with
the onset of dementia in thosepopulations, the result was just
staggering.
SPEAKER_01 (09:03):
The headline result.
Over those seven years, the79-year-olds who received the
vaccine were 20% less likely todevelop dementia compared to the
80-year-olds who did not.
SPEAKER_00 (09:13):
A 20% reduction in dementia risk from a localized
skin rash vaccine.
SPEAKER_01 (09:18):
It sounds like science fiction.
I mean, in the context ofneurodegenerative disease, where
billions of dollars have beenspent on pharmaceuticals that
struggle to slow cognitivedecline by even a fraction of a
percent.
SPEAKER_00 (09:30):
A 20% drop feels like stumbling onto a miracle.
It really does.
SPEAKER_01 (09:35):
Furthermore, the mechanism seems to impact both
the initiation and theprogression of the disease.
SPEAKER_00 (09:40):
Yeah, there was a follow-up study highlighted in
the source published in Decemberin the journal Cell.
SPEAKER_01 (09:46):
Right.
And it found that the vaccinecould also help slow the
progression of dementia inpatients who had already been
diagnosed.
SPEAKER_00 (09:52):
Which implies that if the blood-brain barrier is
beginning to break down in earlydementia, perhaps whatever
systemic protection the vaccineoffers prevents further
catastrophic damage.
SPEAKER_01 (10:02):
And for a listener absorbing this right now, the
immediate instinct is to callthe clinic, book an appointment,
and demand the shot as aneurological shield, like today.
SPEAKER_00 (10:12):
Of course.
But when we transition from thestatisticians looking at the
data to the doctors working withactual patients on the ground,
the tone shifts dramatically.
SPEAKER_01 (10:21):
The medical community is hitting the brakes
hard on this.
SPEAKER_00 (10:24):
And rightly so.
A rigorous scientific approachdemands skepticism, particularly
when a secondary benefit of adrug vastly outperforms the
primary treatments designed forthat specific disease.
SPEAKER_01 (10:36):
The Health Grades article introduces us to two
really strong voices of cautionhere.
Dr.
David Cutler, a family medicinephysician, who explicitly states
he views these findings withdeep skepticism.
SPEAKER_00 (10:48):
And Dr.
Dung Trin, who describes theevidence as encouraging but
firmly maintains it is notpractice-changing at this stage.
SPEAKER_01 (10:56):
Okay, let's tackle Dr.
Trin's primary mechanicalcritique first, because it
uncovers a massive complicationin trying to translate this 2013
Welsh data to a modern Americanclinic in 2026.
SPEAKER_00 (11:07):
It's a huge caveat.
The Stanford researchersanalyzed a cohort that received
a specific vaccine calledZostavax.
SPEAKER_01 (11:14):
Zoskovax, okay, and that's a live attenuated
vaccine, right?
SPEAKER_00 (11:18):
Yes.
It utilizes the OCA strain ofthe Varicella Zoster virus,
which has been passaged throughcell cultures until it is
significantly weakened.
SPEAKER_01 (11:25):
So it is a live virus, but it's hobbled.
SPEAKER_00 (11:27):
Exactly.
It is injected into the body tosimulate a mild systemic
infection.
This forces the immune system torecognize it and build a broad
defense without causing theactual disease.
SPEAKER_01 (11:37):
But the catch is Zostavax is obsolete.
It hasn't been administered inthe United States since 2020.
SPEAKER_00 (11:43):
Right.
Today, the standard of care is acompletely different vaccine
called Shinrix.
SPEAKER_01 (11:48):
And Singrix is a recombinant vaccine which
operates on entirely differentimmunological principles.
It does not contain a live virusat all.
No, it doesn't.
SPEAKER_00 (11:56):
Instead, scientists isolated a single specific
protein from the surface of theVarichella virus claycoprotein
E, and they combine this proteinwith an adjuvant.
SPEAKER_01 (12:05):
The adjuvant is the key here, isn't it?
It's the alarm bell.
Like if you just inject a singledead protein into the arm, the
immune system might just ignoreit entirely.
SPEAKER_00 (12:13):
Precisely.
The immune system needs a dangersignal to wake up.
So Shinrix uses a very powerfuladjuvant system called AS01B.
SPEAKER_01 (12:21):
AS01B, what is that made of?
SPEAKER_00 (12:23):
It contains a compound extracted from the bark
of the Cuagis sapinaria tree,known as QS21, alongside a
bacterial extract.
SPEAKER_01 (12:31):
Bark and bacteria.
SPEAKER_00 (12:32):
Wow.
When this adjuvant enters thetissue, it violently triggers
specific receptors like colireceptor 4 on your innate immune
cells.
It essentially creates alocalized engineered panic.
SPEAKER_01 (12:44):
So the immune system rushes to the site of the
inflammation, encounters theglycoprotein E, and mounts an
aggressive, highly targeteddefense against that specific
protein.
SPEAKER_00 (12:55):
And in terms of its primary job preventing a
shingles rash, this targetedapproach is vastly superior.
The old live vaccine, Zostavax,was only about 51% effective at
reducing the risk of shingles.
SPEAKER_01 (13:08):
Right, 51% is like a coin toss.
But the newer recombinantvaccine, Shingrix, boasts a 90%
efficacy rate.
It is a phenomenal medicalupgrade for shingles.
SPEAKER_00 (13:18):
However, this upgrade creates a massive blind
spot for the dementia data.
As Dr.
Trin points out, we cannotsimply assume that because
Shingrix is better at preventingshingles, it will automatically
be better at preventingdementia.
SPEAKER_01 (13:29):
Wait, really?
Because my initial assumptionwas a straight line.
Like if a 51% effective vaccinegave us a 20% drop in dementia,
a 90% effective vaccine shouldpractically eradicate cognitive
decline.
SPEAKER_00 (13:40):
It's a logical thought, but it's flawed.
You're assuming the mechanism ofaction for dementia prevention
is tied directly to the efficacyagainst the rash.
But the type of immune responsemight be the critical factor.
SPEAKER_01 (13:52):
I see.
SPEAKER_00 (13:52):
It's the defining immunological puzzle here.
A live attenuated vaccine likeZostavax triggers a broad
sprawling immune response.
The body is reacting to a livepathogen.
SPEAKER_01 (14:04):
It activates different types of T cells,
alters the cytokine environmentin the bloodstream, all
differently than a recombinantvaccine does.
SPEAKER_00 (14:12):
Exactly.
Shingrix is a sniper rifle aimedat one protein.
Zostavax was a shotgun blast.
SPEAKER_01 (14:18):
So are we theorizing that the shotgun blast, that
mild systemic viral infectioncaused by the old vaccine, was
somehow responsible for clearingout neurological debris in the
brain?
SPEAKER_00 (14:28):
It's possible.
And if that's true, the new,highly effective Shingrix
vaccine might not offer the samecognitive protection at all.
Wow.
SPEAKER_01 (14:36):
That's a sobering thought.
We just don't know yet.
SPEAKER_00 (14:38):
We do not know.
And until we have longitudinaldata tracking Shingrix
specifically over a decade,physicians cannot ethically
promise patients that therecombinant vaccine will alter
their cognitive trajectory.
SPEAKER_01 (14:49):
Right.
We simply swap the biologicalengine, and we cannot guarantee
the systemic side effects remainexactly the same.
SPEAKER_00 (14:55):
And Dr.
Trin's immunological caution isreally just the first hurdle.
Dr.
Cutler attacks the foundationalpremise of the Stanford study
itself.
SPEAKER_01 (15:03):
Yeah, he highlights the inherent, inescapable flaws
of observational research,focusing heavily on what he
calls residual confounding.
SPEAKER_00 (15:12):
Even with the brilliant regression
discontinuity design, you know,the Welsh bouncer cutoff, Dr.
Cutler points out that variablesstill leak into observational
databases.
SPEAKER_01 (15:21):
He explicitly cites factors like health-seeking
behaviors, frailty trajectories,and access to care.
SPEAKER_00 (15:28):
We really need to define health-seeking behaviors
deeply here because it is theultimate spoiler of medical
statistics.
SPEAKER_01 (15:35):
Let's do it.
Let's look at the psychology ofthe patient.
The person who takes theinitiative to research a
preventative shingles vaccine,call their physician, navigate
their insurance.
SPEAKER_00 (15:44):
And voluntarily take an injection for a disease they
don't even have yet.
SPEAKER_01 (15:48):
Exactly.
That person operates with a highlevel of medical literacy and
personal agency.
SPEAKER_00 (15:53):
It's the healthy user bias.
That same patient isstatistically far more likely to
adhere to a Mediterranean dietor to maintain a consistent
cardiovascular exercise routine.
SPEAKER_01 (16:04):
And they aggressively manage their
cholesterol and blood pressure.
They are more likely to engagein cognitively demanding tasks,
and they generally possess asocioeconomic stability that
reduces chronic stress.
SPEAKER_00 (16:16):
Conversely, the patient who does not get the
vaccine might be on what Dr.
Cutler calls a frailtytrajectory.
SPEAKER_01 (16:22):
Meaning they might already be experiencing the
early subtle onset of physicalor cognitive decline, which
makes it just too difficult toschedule preventative care in
the first place.
SPEAKER_00 (16:31):
Or they simply lack the access to a reliable clinic.
SPEAKER_01 (16:34):
So the core debate emerges.
Are the vaccinated individualsaging slower and retaining their
cognition because the chemicalcomponents of the vaccine are
altering their brain chemistry?
SPEAKER_00 (16:45):
Or does the presence of a shingles vaccination in a
medical chart merely serve as areliable marker for a patient
who was already predisposed to along, healthy life due to a
hundred other daily choices?
SPEAKER_01 (16:58):
It is the ultimate chicken or the egg scenario.
Does the intervention cause thehealth, or does the healthy
person seek the intervention?
SPEAKER_00 (17:06):
But Dr.
Cutler takes this a step furtherin the text.
He introduces a fascinatingdichotomy about how the vaccine
actually functions.
SPEAKER_01 (17:14):
Yeah, this is great.
I'm quoting directly from thearticle here.
The two factors that come to mymind raising the possibility
that shingles vaccines may lowerdementia risk are the vaccine
itself and the avoidance of theshingles disease.
SPEAKER_00 (17:25):
This is a brilliant distillation of the
immunological mystery.
He is separating the activechemical intervention from the
passive biological outcome.
SPEAKER_01 (17:33):
Let's break down mechanism A first, the active
intervention.
In this scenario, the liquid inthe syringe, whether it's the
live virus in Zostavax or theadjuvant in Shingrix, enters the
bloodstream and actively changesthe environment of the brain.
SPEAKER_00 (17:47):
Perhaps it stimulates microglia, which are
the immune cells of the brain,to aggressively hunt down and
clear out amyloid beta plaquesbefore they can form the tangles
associated with Alzheimer'sdisease.
SPEAKER_01 (17:59):
That would be a direct pharmacological effect of
the vaccine.
SPEAKER_00 (18:02):
Right.
But mechanism B is entirelydifferent.
In mechanism B, the vaccine doesabsolutely nothing to the brain.
SPEAKER_01 (18:08):
Because in clear plaques, it doesn't alter brain
chemistry.
SPEAKER_00 (18:11):
All it does is successfully lock the varicella
zoster virus in the nerveganglion, completely preventing
a shingles outbreak.
SPEAKER_01 (18:19):
And why would simply avoiding the outbreak protect
the brain?
SPEAKER_00 (18:22):
Because a full-blown shingles infection is a massive
traumatic physiological event.
SPEAKER_01 (18:27):
Right.
When that virus travels down thenerve and erupts on the skin, it
causes a tremendous spike insystemic inflammation.
It floods the body withcytokines.
SPEAKER_00 (18:37):
And if you are 75 years old and your blood-brain
barrier is already slightlycompromised by age, that massive
wave of systemic viralinflammation could easily cross
into the brain.
SPEAKER_01 (18:47):
Which would accelerate neurodegeneration and
trigger the rapid onset ofdementia.
SPEAKER_00 (18:52):
Think of the vaccine as a highly effective seatbelt.
The physical fabric of theseatbelt does not actively
repair your car's engine, right?
SPEAKER_01 (19:00):
Right.
It doesn't make the car runsmoother.
SPEAKER_00 (19:02):
But wearing the seatbelt prevents you from
flying through the windshieldduring a catastrophic collision.
By entirely avoiding the traumaof the crash, the car and the
driver survive longer.
SPEAKER_01 (19:13):
I love that analogy.
It's like asking if wearing aseatbelt makes your car run
better, or if avoiding a massivecrash is what keeps your car
running better.
And if the cognitive benefit ofthe vaccine relies entirely on
mechanism B simply avoiding thecrash, then our earlier fears
about Shingrix versus Zostavacsare completely inverted.
SPEAKER_00 (19:33):
Exactly.
If the goal is purely to preventthe systemic inflammatory storm
of a viral reactivation, thenShingrix, with its 90% efficacy
rate, should theoretically be avastly superior shield for the
brain than the old 51% effectivevaccine.
SPEAKER_01 (19:47):
But again, we don't have the longitudinal data to
prove which mechanism is thetrue driver yet.
Is it the chemical compositionof the old vaccine or is it the
avoidance of the viral trauma?
SPEAKER_00 (19:57):
It is a phenomenal puzzle.
And just as we are wrestlingwith the mechanics of
neurodegeneration, the sourcematerial throws a second, even
more profound claim onto thetable.
SPEAKER_01 (20:08):
Oh man, here's where it gets really interesting.
We shift our focus from thepreservation of cognitive
function to the fundamentalalteration of the biological
aging process itself.
SPEAKER_00 (20:18):
The article highlights a January study
published in the Journal ofGerontology Series A.
SPEAKER_01 (20:23):
The researchers, including Dr.
John K.
Kenders, a research associateprofessor of gerontology,
utilized the U.S.
Health and Retirement Study.
They examined a massive cohortof over 3,800 participants who
were 70 years of age or older in2016.
SPEAKER_00 (20:38):
And they moved beyond diagnostic codes for
dementia.
They looked closely at theactual physiological and
molecular markers of cellularaging.
SPEAKER_01 (20:46):
They assessed seven distinct pillars of biological
age.
I want to list these out becauseit's intense: inflammation,
innate immunity, adaptiveimmunity, cardiovascular
hemodynamics, neurodegeneration,epigenetic aging, and
transcriptomic aging.
SPEAKER_00 (20:59):
And the findings were staggering.
SPEAKER_01 (21:01):
The individuals who had received a shingles vaccine
demonstrated a significantlylower composite biological aging
score.
They were, at a cellular level,younger than their chronological
AIDS would suggest.
SPEAKER_00 (21:13):
We really need to dissect these seven markers
because they map out the exactpathways where a virus and a
vaccine might be manipulatingour internal clocks.
SPEAKER_01 (21:22):
Let's do it.
The first three markers aredeeply intertwined with the
immune system (21:25):
inflammation, innate immunity, and adaptive
immunity.
Let's start with inflammation.
SPEAKER_00 (21:32):
Systemic inflammation is essentially the
bedrock of aging.
When we talk about measuringinflammation, we're usually
looking at biomarkers in theblood, like C reactive protein
or CRP or interleukin 6.
SPEAKER_01 (21:44):
High levels indicate the body is in a constant low
grade state of alarm.
SPEAKER_00 (21:48):
Yes.
And this leads directly into themeasurements of innate and
adaptive immunity.
The innate immune system is yourbroad immediate response.
Cells like macrophages andneutrophils that attack any
form.
Or an invader indiscriminately.
SPEAKER_01 (22:01):
And the adaptive system, like we discussed
earlier with T cells and Bcells, is the highly specialized
memory-driven response.
SPEAKER_00 (22:08):
Right.
As we age, both systems degrade.
The innate system often becomeshyperactive, contributing to
that chronic inflammation, whilethe adaptive system becomes
exhausted, losing its ability tofight off specific, novel
threats.
SPEAKER_01 (22:23):
So the vaccinated group showed better preservation
of these immune architectures.
That's huge.
The fourth marker they analyzedwas cardiovascular hemodynamics.
SPEAKER_00 (22:33):
This refers to the physical mechanics of blood
flow.
How stiff are the arteries, howresponsive is the endothelial
lining of the blood vessels.
SPEAKER_01 (22:41):
Because chronic viral infections and systemic
inflammation cause immense sheerstress on the vascular system,
don't they?
SPEAKER_00 (22:47):
They absolutely do.
If a vaccine reduces thatinflammatory burden, the blood
vessels retain their elasticitylonger, ensuring optimal blood
flow, not just to the heart, butto the microvasculature of the
brain.
SPEAKER_01 (22:58):
Aaron Powell, which bridges perfectly to the fifth
marker, neurodegeneration.
And this isn't just a cognitivetest, right?
SPEAKER_00 (23:03):
No, researchers can look at physical biomarkers like
neurofilament light chainproteins in the blood, which
only appear when structuraldamage is occurring to the
neurons themselves.
SPEAKER_01 (23:12):
Okay, but the final two markers are where the
concept of biological agingbecomes truly molecular,
epigenetic aging andtranscriptomic aging.
Can you translate this heavyjargon for us?
Let's plunge into the deep endof the cellular pool.
Epigenetics.
SPEAKER_00 (23:28):
Gladly.
We know our DNA is a fixedinstruction manual.
You are born with a specificsequence of genes, and barring a
mutation, that sequence does notchange.
SPEAKER_01 (23:37):
But how those genes are expressed changes
constantly.
SPEAKER_00 (23:40):
Exactly.
The primary mechanism ofepigenetic aging involves DNA
methylation.
Chemical tags, known as methylgroups, attach themselves to
specific sites on your DNA.
SPEAKER_01 (23:50):
And these tags act as volume knobs, turning the
expression of certain genes upor down.
SPEAKER_00 (23:55):
As we age, the placement of these methyl tags
becomes erratic.
Essential repair genes might getturned off, while inflammatory,
degrading genes get permanentlyturned on.
SPEAKER_01 (24:03):
And scientists use epigenetic clocks like the
Horvath clock to read thesemethylation patterns and
determine a person's truebiological age.
SPEAKER_00 (24:11):
Yes, and transcriptomic aging takes it a
step further down the assemblyline.
SPEAKER_01 (24:16):
Okay, so the DNA is the manual, but the RNA is the
messenger.
Transcriptomics is the study ofmessenger RNA, right?
SPEAKER_00 (24:22):
Correct.
It looks at how accurately thegenetic instructions are being
transcribed and carried to theribosomes to build proteins.
SPEAKER_01 (24:29):
And in an aging cell, transcription becomes
sloppy.
SPEAKER_00 (24:32):
Very sloppy.
The cell starts producingmisfolded proteins, or it stops
producing critical maintenanceenzymes altogether.
The cellular environmentbasically becomes cluttered with
biological junk.
SPEAKER_01 (24:43):
But according to this study, the shingles vaccine
was correlated with slowerepigenetic and transcriptomic
aging.
The vaccinated individuals hadcleaner DNA methylation patterns
and more accurate RNAtranscription.
SPEAKER_00 (24:55):
Which begs the question.
SPEAKER_01 (24:56):
Yeah, how is it physically possible that an
injection targeting a dormantchicken pox virus keeps the
cellular instruction manualrunning like a younger machine?
SPEAKER_00 (25:05):
Dr.
Young Key Kim offers a verycompelling hypothesis here,
centered around the concept ofbackground inflammation.
SPEAKER_01 (25:11):
Okay, let's bring our sleeper agent analogy back.
The varicilla virus is hiding inthe nerve ganglion.
It is being guarded by aging Tcells.
What if the virus isn'tperfectly dormant?
What if it's restless?
SPEAKER_00 (25:23):
In immunology, we call this subclinical
reactivation.
The virus is constantlyattempting to multiply.
It pushes against the weakened Tcell perimeter.
SPEAKER_01 (25:33):
And the immune system detects this minor breach
and mounts a small, localizedresponse to beat the virus back
into latency.
SPEAKER_00 (25:41):
Exactly.
You never develop a rash, younever feel neuropathic pain, you
have no idea this microscopicwar is happening.
SPEAKER_01 (25:47):
But the war generates heat.
SPEAKER_00 (25:48):
Yes.
The constant repetitive cycle ofsubclinical reactivation and
immune suppression creates asteady drip of inflammatory
cytokines into the bloodstream.
SPEAKER_01 (25:58):
This is the background inflammation Dr.
Kim refers to.
SPEAKER_00 (26:01):
It is like a stove burner left on a low simmer for
decades.
That simmering heat damages theendothelial lining of your blood
vessels.
It exhausts your adaptive immunecells.
SPEAKER_01 (26:10):
And critically, it disrupts the delicate epigenetic
machinery, causing the erraticDNA methylation that accelerates
biological aging.
SPEAKER_00 (26:18):
But by administering the shingles vaccine, you are
sending massive reinforcementsto the perimeter.
SPEAKER_01 (26:23):
You boost the T cell response so aggressively that
the virus is forced into a muchdeeper state of latency.
SPEAKER_00 (26:29):
The subclinical reactivations cease, the
microscopic war ends.
SPEAKER_01 (26:33):
The stove is turned off.
SPEAKER_00 (26:34):
And without that constant simmering background
inflammation, your epigenetictags stabilize, your RNA
transcription cleans up, yourcells are no longer aging under
the stress of a hidden chronicviral load.
SPEAKER_01 (26:47):
It is a breathtaking biological theory.
The idea that a single latentchildhood virus is quietly
acting as a chronometer, takingaway our biological youth, and
that a vaccine can simply pausethe clock.
SPEAKER_00 (27:00):
It is beautiful in its elegance.
But and there's always a but Dr.
Trin is waiting in the wings tobring us back to epidemiological
reality here, too.
SPEAKER_01 (27:08):
Right.
He explicitly labels thefindings in the biological aging
paper as hypothesis generating.
SPEAKER_00 (27:14):
Because he levels the exact same critique here
that Dr.
Cutler aimed at the dementiastudy.
Observational data, residualconfounding.
SPEAKER_01 (27:20):
Are the people in the U.S.
Health and Retirement Studyexhibiting youthful
transcriptomic profiles becausethey received the shingles
vaccine?
SPEAKER_00 (27:28):
Or did they receive the shingles vaccine because
they belong to a socioeconomicdemographic that affords them
low stress environments, highquality nutrition, and early
medical intervention?
SPEAKER_01 (27:37):
All of which profoundly influence DNA
methylation and systemicinflammation completely
independently of any vaccine.
SPEAKER_00 (27:45):
Right.
Even when biostatisticians buildcomplex models to mathematically
adjust for income, education,and observable health behaviors,
it is practically impossible toperfectly isolate the biological
effect of a single vaccine fromthe sprawling reality of a human
life.
SPEAKER_01 (28:00):
Which brings us to the ultimate question for you,
the listener.
We have analyzed incrediblyexciting, statistically
significant data from massivepopulation studies, data
suggesting that the shinglesvaccine might protect the brain
and slow the cellular agingclock.
SPEAKER_00 (28:15):
And we have also examined the rigorous structural
skepticism from physicians whowarn against conflating
correlation with causation,especially when dealing with
fundamentally different vaccinemechanics, like Zostavax versus
Shingrix.
SPEAKER_01 (28:30):
So we have incredibly exciting data weighed
against heavy medicalskepticism.
Where does that leave you whenyou visit your doctor tomorrow?
What is the actionable strategyhere?
SPEAKER_00 (28:40):
The strategy requires embracing what Dr.
Trin calls the bonus philosophy.
But first, we must adhere to theestablished medical guidelines
explicitly detailed in thesource material.
SPEAKER_01 (28:50):
Right, let's look at the current CDC guidelines,
which are clear and currentlyuninfluenced by the dementia or
aging data.
SPEAKER_00 (28:57):
The CDC recommends two doses of the shingles
vaccine for adults who are ages50 and older.
SPEAKER_01 (29:02):
Furthermore, they recommend it for adults 19 years
and older who are or will beimmunodeficient or
immunosuppressed due to diseaseor therapy.
SPEAKER_00 (29:10):
And those two doses are administered two to six
months apart.
If you meet these demographiccriteria, the medical consensus
is completely unified.
You should receive the vaccineto prevent the devastating
neuropathic pain andcomplications of a shingles
outbreak.
SPEAKER_01 (29:26):
But regarding the secondary benefits, Dr.
Trin states his advice topatients plainly.
He says, do it for shinglesprevention.
Any cognitive or aging benefitwould be a bonus if future
trials confirm it.
SPEAKER_00 (29:38):
It's the only rational approach.
You are purchasing theintervention to stop the virus.
If in 10 years randomizedcontrol trials prove that
shingrix also preserved yourepigenetic clock and shielded
your blood-brain barrier, youreap a massive dividend.
SPEAKER_01 (29:52):
But you cannot rely on a theoretical dividend as
your primary cognitive defensestrategy.
SPEAKER_00 (29:56):
Absolutely not.
Because we already possess ahighly effective proven arsenal
for dementia prevention.
SPEAKER_01 (30:03):
Yes.
Dr.
Cutler outlines 10 specificlifestyle adjustments in the
article.
People constantly search for apharmaceutical magic bullet to
save their brain while totallyignoring the difficult daily
maintenance that fundamentallyalters neurodegeneration.
SPEAKER_00 (30:17):
If we connect this to the bigger picture, we need
to dissect his list becausethese aren't just generic
platitudes, they are powerfulbiological levers.
SPEAKER_01 (30:25):
Let's begin with the cardiovascular foundation.
Dr.
Cutler lists controlling bloodpressure, keeping cholesterol in
check, avoiding tobacco use, andlimiting alcohol consumption.
SPEAKER_00 (30:36):
We discussed cardiovascular hemodynamics
earlier.
The brain is the mostmetabolically demanding organ in
the body.
It requires a massive,uninterrupted flow of oxygen and
nutrients through a delicatenetwork of microvessels.
SPEAKER_01 (30:51):
And chronic high blood pressure creates sheer
stress that damages theendothelial lining of these
vessels, leading to microbleedsand vascular dementia.
SPEAKER_00 (31:00):
Exactly.
High cholesterol drivesatherosclerosis, literally
choking off the cerebral bloodsupply over time.
SPEAKER_01 (31:06):
And tobacco introduces immense oxidative
stress and chemical toxinsdirectly into the bloodstream,
rapidly accelerating endothelialdysfunction.
SPEAKER_00 (31:14):
While alcohol is a direct neurotoxin that not only
damages neurons but severelydisrupts the architecture of
restorative sleep.
SPEAKER_01 (31:20):
This leads perfectly to his next points regular
physical exercise, eating ahealthy diet, preventing and
controlling diabetes, andmaintaining a healthy body
weight.
SPEAKER_00 (31:30):
These are the primary regulators of systemic
inflammation.
Adipose tissue body fat is notsimply inert storage, it is an
active endocrine organ thatsecretes inflammatory cytokines.
SPEAKER_01 (31:41):
So maintaining a healthy weight directly reduces
the simmering heat we discussedearlier.
SPEAKER_00 (31:46):
Yes.
And preventing diabetes preventsinsulin resistance in the brain,
a condition so closely linked toAlzheimer's that some
researchers refer to the diseaseas type 3 diabetes.
SPEAKER_01 (31:57):
And physical exercise does more than just
pump blood, right?
It triggers the release ofbrain-derived neurotrophic
factor, or BDNF.
SPEAKER_00 (32:04):
BDNF is essentially a fertilizer for the brain.
It stimulates neurogenesis, thecreation of new neurons,
particularly in the hippocampus,the region responsible for
memory and learning.
SPEAKER_01 (32:14):
The final two adjustments on Dr.
Cutler's list target theneurological architecture
directly, getting adequate sleepand avoiding social isolation.
SPEAKER_00 (32:21):
Sleep is not merely a period of inactivity, it is an
aggressive mechanical cleaningcycle.
SPEAKER_01 (32:26):
Oh, the glymphatic system.
I love this topic.
Deep sleep activates theglymphatic system.
The astrocytes, the supportcells in your brain, literally
shrink in size.
SPEAKER_00 (32:37):
Allowing cerebrospinal fluid to rush
through the brain tissue andwash away the toxic metabolic
waste that accumulates duringwaking hours.
SPEAKER_01 (32:44):
Including the amyloid beta proteins implicated
in dementia.
If you chronically restrictsleep, the trash just piles up.
SPEAKER_00 (32:51):
And avoiding social isolation addresses the
cognitive reserve hypothesis.
The human brain is an intenselysocial computational engine.
SPEAKER_01 (32:59):
Engaging in complex conversation, navigating
empathy, maintainingrelationships, it all requires
massive, continuousneuroplasticity.
SPEAKER_00 (33:08):
Isolation deprives the brain of its primary
stimulus, causing the synapticnetworks to atrophy from disuse.
SPEAKER_01 (33:14):
It is such a comprehensive, empowering list.
You do not need to wait for adecade of clinical trials to
turn down your systemicinflammation.
You do not need a vaccine tostimulate your lymphatic system
tonight.
SPEAKER_00 (33:25):
No, you don't.
A brisk walk, a tightlycontrolled blood sugar level, a
solid eight hours of sleep, anda meaningful conversation with a
friend are the most powerfulepigenetic regulators currently
available to you.
SPEAKER_01 (33:39):
Modern medicine doesn't rely on magic bullets.
As Dr.
Cutler notes, it would be aphenomenal advance if a simple
safe vaccine could eventually beadded to this protective
arsenal.
SPEAKER_00 (33:49):
But a medical intervention will only ever
complement, not replace, thefoundational physiology built by
daily habits.
SPEAKER_01 (33:56):
So what does this all mean?
We have covered a tremendousamount of ground today.
We started by examining theterrifying latency of the
Varicella's Oscar virus, asleeper agent hiding in the
sensory ganglia, waiting for theimmune system to falter.
SPEAKER_00 (34:09):
We explored how the brilliant regression
discontinuity design of theStanford study revealed a 20%
drop in dementia risk.
SPEAKER_01 (34:16):
And how researchers are desperately trying to
unravel the biologicalmechanisms driving that drop.
We waded through the criticalskepticism of the medical
community, unpacking theprofound differences between
live-attenuated and recombinantvaccines.
SPEAKER_00 (34:28):
And acknowledging the inescapable shadow of
residual confounding inobservational data.
SPEAKER_01 (34:34):
We explored the beautiful theory that
suppressing subclinical viralreactivation might turn off the
chronic background inflammationthat accelerates our epigenetic
and transcriptomic aging clocks.
SPEAKER_00 (34:45):
It really highlights a thrilling evolution in medical
science.
We're moving away from viewingthe body as a collection of
isolated systems.
SPEAKER_01 (34:53):
We're beginning to understand that the immune
response to a nerve ganglioninfection in your spine is
inextricably linked to themolecular aging of your
cardiovascular system and thepreservation of your cerebral
cortex.
The web is entirely connected.
SPEAKER_00 (35:08):
But true health literacy requires patience.
Knowledge is only valuable whenapplied with critical thinking.
The headlines offer immediate,miraculous answers.
The science demands rigorouslongitudinal clinical trials.
SPEAKER_01 (35:20):
To differentiate the active effects of an adjuvant
from the passive benefits ofavoiding a viral trauma, you
must use the data to inform yourunderstanding, not to replace
your foundational healthstrategies.
SPEAKER_00 (35:31):
Exactly.
We must be patient for thescience to catch up to the
headlines.
SPEAKER_01 (35:35):
But before we sign off, I want to leave you, the
listener, with one final deeplyprovocative thought that stems
directly from everything we'vediscussed today.
SPEAKER_00 (35:44):
Proceed.
SPEAKER_01 (35:44):
We have spent all this time dissecting the
profound systemic damage causedby just one virus, the Vericella
zoster virus.
A virus most of us acquired inchildhood that we assumed we
defeated, but which quietly setup latency in our nervous
system, subtly exhausting our Tcells and dripping inflammatory
cytokines into our bloodstreamfor decades.
(36:06):
If preventing the localizedreactivation of just this single
dormant virus can theoreticallyalter our neurodegeneration and
drastically lower our compositebiological aging scores, how
many other seemingly harmlesslatent viruses are quietly
sleeping in our cellulararchitecture right now?
SPEAKER_00 (36:23):
Like Epstein-Barr or Cytomegalovirus.
SPEAKER_01 (36:26):
Exactly.
Are they generating backgroundinflammation and silently
accelerating our biologicalclocks without us ever realizing
the war is happening?
SPEAKER_00 (36:33):
That is the frontier of immunology, and it is a
question that will redefine howwe approach aging in the coming
decades.
SPEAKER_01 (36:38):
Something to mull over while you activate your
lymphatic system tonight.
Thank you for joining us on thisdeep dive into the complex,
fiercely debated, and incrediblyhopeful edge of medical science.
We'll catch you next time.
What if um what if the secret to slowing down your
biological clock and likeactually fending off dementia
has just been sitting in yourlocal pharmacy this whole time?
SPEAKER_00 (00:09):
Yeah, disguised as a common skin rash vaccine, right?
It's it's the kind of questionthat forces us to completely
rethink how we view preventativemedicine altogether.
SPEAKER_01 (00:17):
Aaron Powell Exactly.
I mean, we are so used to thesehighly targeted treatments like
you take a pill for bloodpressure or you get a cast for a
broken bone.
SPEAKER_00 (00:25):
Aaron Powell Right, very one-to-one solutions.
But the idea that a singlestandard inoculation could
ripple out and uh protect thebrain's architecture years down
the line, that is a massiveparadigm shift.
SPEAKER_01 (00:36):
Aaron Powell And it's not just some abstract
theory anymore, which is wild.
Today our mission on this deepdive is to tear into this
updated February 2026 healthgrades article.
SPEAKER_00 (00:46):
By David Mills, I believe.
SPEAKER_01 (00:47):
Yeah.
Written by David Mills andfact-checked by Jennifer Chisak.
And the title just lays it outperfectly.
Shingles Vaccines and Dementia,promising data, early evidence.
SPEAKER_00 (00:57):
It's a great piece.
SPEAKER_01 (00:58):
It really is.
So we are going to unpack themassive, groundbreaking studies
driving this whole conversation.
But uh we're also going toconfront the intense medical
skepticism that's kind ofpushing back against the hype
right now.
SPEAKER_00 (01:14):
Aaron Powell Because navigating that tension, you
know, the space between aphenomenal statistical
correlation and an actual provenmedical treatment is where the
real understanding happens.
Right.
For anyone listening who is likeactively trying to map out a
long-term strategy for theircognitive health, simply reading
those flashy headlines isn'tenough.
We really need to dissect thewhy and the how.
SPEAKER_01 (01:35):
We have to get into the weeds, look at the cellular
mechanisms, the epidemiologicalblind spots, all of it.
SPEAKER_00 (01:40):
Exactly.
And the fundamental differencesbetween the vaccines themselves,
which is a huge part of thispuzzle.
SPEAKER_01 (01:45):
Aaron Powell Okay, let's unpack this.
SPEAKER_00 (01:46):
Okay.
SPEAKER_01 (01:47):
Because to grasp how a vaccine might protect your
brain, we first have tounderstand the specific enemy it
was built to fight.
And uh the shingles virus is auniquely insidious foe.
SPEAKER_00 (01:58):
Aaron Powell It really is.
We are not talking about a germyou catch from a doorknob, get
sick from for a week, and thenjust clear from your system.
SPEAKER_01 (02:03):
Aaron Powell Not at all.
The story of shingles actuallybegins decades before the rash
ever appears.
It begins with chickenpox.
SPEAKER_00 (02:11):
Right, the varicella zoster virus.
Right.
Or herpes zoster, which is thepathogen responsible for chicken
pox.
SPEAKER_01 (02:16):
Aaron Powell And for the vast majority of adults
alive today, especially thosewho grew up before the varicella
vaccine became, you know, astandard childhood memionation,
an infection was just auniversal rite of passage.
SPEAKER_00 (02:30):
Oh, absolutely.
You got the itchy spots, youstayed home from school, maybe
you even wore oven mitts to stopyourself from scratching, right?
SPEAKER_01 (02:36):
Aaron Powell Yeah, the oatmeal baths.
And eventually your immunesystem mounts a defense, the
spots fade, and you just assumethe battle is over.
You think the virus is gone.
SPEAKER_00 (02:45):
But the virus was not gone.
That is the crucial part.
The varicella zostovirus ishighly adept at evasion.
SPEAKER_01 (02:51):
It's a sneaky one.
SPEAKER_00 (02:52):
Very.
During that initial childhoodinfection, while your immune
system was busy, you know,clearing the virus from your
skin and bloodstream, viralparticles were silently
retreating.
SPEAKER_01 (03:02):
Retreating where?
SPEAKER_00 (03:03):
They travel along your nerve fibers, they move
away from the skin and go deepinto your body's sensory nervous
system.
SPEAKER_01 (03:09):
It's so creepy to think about.
They act as sleeper agents.
They literally slip past theactive war zone and find a
hiding place where the immunesystem just won't hunt them
down.
SPEAKER_00 (03:18):
Specifically, they set up latency in the dorsal
root ganglia and the cranialnerve ganglia.
SPEAKER_01 (03:24):
Which are what exactly?
For the listeners who aren'tneurologists.
SPEAKER_00 (03:27):
Right.
So these are essentiallyclusters of nerve cell bodies
located just outside the spinalcord and at the base of the
brain.
The viral DNA enters these nervecells and exists as what we call
an episome.
SPEAKER_01 (03:39):
An episome.
Okay, I mean, what does thatactually look like in the cell?
SPEAKER_00 (03:42):
Aaron Powell Well, it means it doesn't integrate
directly into your human DNA.
It just sits there, dormant,entirely self-contained.
It completely halts its ownreplication.
SPEAKER_01 (03:52):
So it just sits in the dark for 20, 40, maybe 60
years.
SPEAKER_00 (03:55):
It waits.
And it is kept in check by youradaptive immune system,
specifically a type of whiteblood cell known as a memory T
cell.
SPEAKER_01 (04:03):
Okay, so the T cells are like the prism guards.
SPEAKER_00 (04:05):
That's a great analogy.
These T cells act as permanentguards, constantly patrolling
the ganglia.
If the virus tries to replicateand wake up, the T cells
immediately shut it down beforeyou ever feel a single symptom.
SPEAKER_01 (04:18):
But as we age, we go through this process called
immunosnescence, right?
Our immune system naturallystarts to weaken.
SPEAKER_00 (04:24):
Exactly.
The T cell patrols become lessfrequent, and the individual
cells themselves become lesseffective.
SPEAKER_01 (04:30):
The guards get tired, the perimeter weakens,
and that sleeper agent finallysees its window to strike.
SPEAKER_00 (04:37):
And that is when the virus reactivates.
It begins to multiply inside thenerve ganglion, which causes
severe inflammation.
Then it uses the nerve fiberitself as a highway.
SPEAKER_01 (04:48):
Traveling all the way back up to the surface of
the skin.
SPEAKER_00 (04:50):
Yes, and this causes the characteristic Kringles
rash.
But because the virus isliterally traversing and
damaging the sensory nervetissue along the way, the
defining characteristic ofshingles is profound, agonizing
neuropathic pain.
SPEAKER_01 (05:04):
Yeah, this isn't just a bad itch.
The source text fromHealthGrades cites Dr.
Dun Trin, an internist whotreats this regularly.
SPEAKER_00 (05:10):
He's very clear about the severity.
SPEAKER_01 (05:12):
He really is.
He makes it clear that shinglesis common, it is intensely
painful, and the consequencescompound significantly with age.
Some people develop a conditioncalled posttherpetic neuralgia.
SPEAKER_00 (05:24):
Which is devastating.
That's where the nerve damage isso severe that the burning
stabbing pain persists formonths, sometimes even years
long after the skin has actuallyhealed.
SPEAKER_01 (05:34):
And the sheer scale of the problem is difficult to
overstate.
The CDC statistic highlighted inthe article is pretty sobering.
One in three people in theUnited States will develop
shingles in their lifetime.
SPEAKER_00 (05:45):
One in three.
When a condition impacts a thirdof the entire population, the
medical system has to respondwith a massive intervention.
SPEAKER_01 (05:53):
Which is why the push for shingles vaccination in
older adults is so aggressiveright now.
The goal is to um artificiallyboost those aging T cells,
right?
SPEAKER_00 (06:03):
Exactly.
You're reinforcing the guard andtrying to keep that sleeper
agent locked in the gangliaforever.
SPEAKER_01 (06:08):
And that aggressive public health campaign is
exactly what paved the way forthese wild dementia findings.
SPEAKER_00 (06:14):
Because we are administering millions and
millions of doses of thisvaccine.
SPEAKER_01 (06:18):
Right.
And when you have a data set,that massive modern epidemiology
allows you to look past theprimary goal of the
intervention.
You start to observe secondaryeffects that literally no one
anticipated.
SPEAKER_00 (06:30):
What's fascinating here is how they found this,
which brings us to the WelshBouncer study.
SPEAKER_01 (06:35):
Yes, let's talk about the Welsh Bouncer.
We need to look at this initialstudy led by researchers at
Stanford University, which waspublished in the journal Nature.
SPEAKER_00 (06:43):
They examined the health records of over 280,000
older adults in Wales, ages 71to 88.
SPEAKER_01 (06:50):
And the methodology here is what elevates this from
just like a casual observationto a highly rigorous
epidemiological tool.
They didn't just look at whochose to get a vaccine and who
didn't over a random decade.
SPEAKER_00 (07:03):
No, they zeroed in on a very specific national
vaccination program that wasrolled out in Wales with an
exact starting date.
SPEAKER_01 (07:10):
September 1st, 2013.
SPEAKER_00 (07:12):
Right.
And the government attached anincredibly rigid arbitrary rule
to this rollout.
SPEAKER_01 (07:17):
It's so bureaucratic, but it's brilliant
for science.
If you were 79 years old onSeptember 1st, 2013, you were
eligible to receive the shinglesvaccine.
SPEAKER_00 (07:26):
But if you were 80 years old or older on that exact
date, you were cut off.
No vaccine for you.
SPEAKER_01 (07:33):
So Dr.
Pascal Geldsesser, an assistantprofessor of medicine at
Stanford and the senior authorof subsequent study, pointed out
that this rigid cutoffessentially mimics a randomized
clinical trial.
SPEAKER_00 (07:45):
In statistics, we call this a regression
discontinuity design.
SPEAKER_01 (07:49):
Okay, let's visualize this cutoff like a
bouncer at a club on September1st.
Two people walk up to the door.
They are neighbors.
SPEAKER_00 (07:57):
They eat the same diet, they have the same
baseline cardiovascular health.
SPEAKER_01 (08:00):
Yeah, the exact same socioeconomic status.
But one of them was born onAugust 31st, making them 80
years old.
The other was born on September2nd, making them 79 years old.
SPEAKER_00 (08:10):
So the 79-year-old gets VIP access, they are
granted the intervention, andthe 80-year-old is turned away
at the door.
SPEAKER_01 (08:16):
They're biologically practically identical.
They're separated by days, yetone is suddenly placed in a
vaccinated cohort, and the otheris placed in an unvaccinated
control group.
SPEAKER_00 (08:26):
And this mathematical quirk naturally
filters out the massive muddyingvariables that usually plague
observational research.
SPEAKER_01 (08:33):
Right, because usually we have to worry that
wealthy people were more likelyto buy the vaccine or that super
health conscious people soughtit out.
SPEAKER_00 (08:40):
But here, the sole determining factor was an
arbitrary line drawn in the sandby a health ministry.
SPEAKER_01 (08:46):
It's incredible.
By tracking these two perfectlydivided groups over a seven-year
period, the Stanford researcherswere able to isolate the effect
of the vaccine itself.
SPEAKER_00 (08:57):
And when they cross-referenced that data with
the onset of dementia in thosepopulations, the result was just
staggering.
SPEAKER_01 (09:03):
The headline result.
Over those seven years, the79-year-olds who received the
vaccine were 20% less likely todevelop dementia compared to the
80-year-olds who did not.
SPEAKER_00 (09:13):
A 20% reduction in dementia risk from a localized
skin rash vaccine.
SPEAKER_01 (09:18):
It sounds like science fiction.
I mean, in the context ofneurodegenerative disease, where
billions of dollars have beenspent on pharmaceuticals that
struggle to slow cognitivedecline by even a fraction of a
percent.
SPEAKER_00 (09:30):
A 20% drop feels like stumbling onto a miracle.
It really does.
SPEAKER_01 (09:35):
Furthermore, the mechanism seems to impact both
the initiation and theprogression of the disease.
SPEAKER_00 (09:40):
Yeah, there was a follow-up study highlighted in
the source published in Decemberin the journal Cell.
SPEAKER_01 (09:46):
Right.
And it found that the vaccinecould also help slow the
progression of dementia inpatients who had already been
diagnosed.
SPEAKER_00 (09:52):
Which implies that if the blood-brain barrier is
beginning to break down in earlydementia, perhaps whatever
systemic protection the vaccineoffers prevents further
catastrophic damage.
SPEAKER_01 (10:02):
And for a listener absorbing this right now, the
immediate instinct is to callthe clinic, book an appointment,
and demand the shot as aneurological shield, like today.
SPEAKER_00 (10:12):
Of course.
But when we transition from thestatisticians looking at the
data to the doctors working withactual patients on the ground,
the tone shifts dramatically.
SPEAKER_01 (10:21):
The medical community is hitting the brakes
hard on this.
SPEAKER_00 (10:24):
And rightly so.
A rigorous scientific approachdemands skepticism, particularly
when a secondary benefit of adrug vastly outperforms the
primary treatments designed forthat specific disease.
SPEAKER_01 (10:36):
The Health Grades article introduces us to two
really strong voices of cautionhere.
Dr.
David Cutler, a family medicinephysician, who explicitly states
he views these findings withdeep skepticism.
SPEAKER_00 (10:48):
And Dr.
Dung Trin, who describes theevidence as encouraging but
firmly maintains it is notpractice-changing at this stage.
SPEAKER_01 (10:56):
Okay, let's tackle Dr.
Trin's primary mechanicalcritique first, because it
uncovers a massive complicationin trying to translate this 2013
Welsh data to a modern Americanclinic in 2026.
SPEAKER_00 (11:07):
It's a huge caveat.
The Stanford researchersanalyzed a cohort that received
a specific vaccine calledZostavax.
SPEAKER_01 (11:14):
Zoskovax, okay, and that's a live attenuated
vaccine, right?
SPEAKER_00 (11:18):
Yes.
It utilizes the OCA strain ofthe Varicella Zoster virus,
which has been passaged throughcell cultures until it is
significantly weakened.
SPEAKER_01 (11:25):
So it is a live virus, but it's hobbled.
SPEAKER_00 (11:27):
Exactly.
It is injected into the body tosimulate a mild systemic
infection.
This forces the immune system torecognize it and build a broad
defense without causing theactual disease.
SPEAKER_01 (11:37):
But the catch is Zostavax is obsolete.
It hasn't been administered inthe United States since 2020.
SPEAKER_00 (11:43):
Right.
Today, the standard of care is acompletely different vaccine
called Shinrix.
SPEAKER_01 (11:48):
And Singrix is a recombinant vaccine which
operates on entirely differentimmunological principles.
It does not contain a live virusat all.
No, it doesn't.
SPEAKER_00 (11:56):
Instead, scientists isolated a single specific
protein from the surface of theVarichella virus claycoprotein
E, and they combine this proteinwith an adjuvant.
SPEAKER_01 (12:05):
The adjuvant is the key here, isn't it?
It's the alarm bell.
Like if you just inject a singledead protein into the arm, the
immune system might just ignoreit entirely.
SPEAKER_00 (12:13):
Precisely.
The immune system needs a dangersignal to wake up.
So Shinrix uses a very powerfuladjuvant system called AS01B.
SPEAKER_01 (12:21):
AS01B, what is that made of?
SPEAKER_00 (12:23):
It contains a compound extracted from the bark
of the Cuagis sapinaria tree,known as QS21, alongside a
bacterial extract.
SPEAKER_01 (12:31):
Bark and bacteria.
SPEAKER_00 (12:32):
Wow.
When this adjuvant enters thetissue, it violently triggers
specific receptors like colireceptor 4 on your innate immune
cells.
It essentially creates alocalized engineered panic.
SPEAKER_01 (12:44):
So the immune system rushes to the site of the
inflammation, encounters theglycoprotein E, and mounts an
aggressive, highly targeteddefense against that specific
protein.
SPEAKER_00 (12:55):
And in terms of its primary job preventing a
shingles rash, this targetedapproach is vastly superior.
The old live vaccine, Zostavax,was only about 51% effective at
reducing the risk of shingles.
SPEAKER_01 (13:08):
Right, 51% is like a coin toss.
But the newer recombinantvaccine, Shingrix, boasts a 90%
efficacy rate.
It is a phenomenal medicalupgrade for shingles.
SPEAKER_00 (13:18):
However, this upgrade creates a massive blind
spot for the dementia data.
As Dr.
Trin points out, we cannotsimply assume that because
Shingrix is better at preventingshingles, it will automatically
be better at preventingdementia.
SPEAKER_01 (13:29):
Wait, really?
Because my initial assumptionwas a straight line.
Like if a 51% effective vaccinegave us a 20% drop in dementia,
a 90% effective vaccine shouldpractically eradicate cognitive
decline.
SPEAKER_00 (13:40):
It's a logical thought, but it's flawed.
You're assuming the mechanism ofaction for dementia prevention
is tied directly to the efficacyagainst the rash.
But the type of immune responsemight be the critical factor.
SPEAKER_01 (13:52):
I see.
SPEAKER_00 (13:52):
It's the defining immunological puzzle here.
A live attenuated vaccine likeZostavax triggers a broad
sprawling immune response.
The body is reacting to a livepathogen.
SPEAKER_01 (14:04):
It activates different types of T cells,
alters the cytokine environmentin the bloodstream, all
differently than a recombinantvaccine does.
SPEAKER_00 (14:12):
Exactly.
Shingrix is a sniper rifle aimedat one protein.
Zostavax was a shotgun blast.
SPEAKER_01 (14:18):
So are we theorizing that the shotgun blast, that
mild systemic viral infectioncaused by the old vaccine, was
somehow responsible for clearingout neurological debris in the
brain?
SPEAKER_00 (14:28):
It's possible.
And if that's true, the new,highly effective Shingrix
vaccine might not offer the samecognitive protection at all.
Wow.
SPEAKER_01 (14:36):
That's a sobering thought.
We just don't know yet.
SPEAKER_00 (14:38):
We do not know.
And until we have longitudinaldata tracking Shingrix
specifically over a decade,physicians cannot ethically
promise patients that therecombinant vaccine will alter
their cognitive trajectory.
SPEAKER_01 (14:49):
Right.
We simply swap the biologicalengine, and we cannot guarantee
the systemic side effects remainexactly the same.
SPEAKER_00 (14:55):
And Dr.
Trin's immunological caution isreally just the first hurdle.
Dr.
Cutler attacks the foundationalpremise of the Stanford study
itself.
SPEAKER_01 (15:03):
Yeah, he highlights the inherent, inescapable flaws
of observational research,focusing heavily on what he
calls residual confounding.
SPEAKER_00 (15:12):
Even with the brilliant regression
discontinuity design, you know,the Welsh bouncer cutoff, Dr.
Cutler points out that variablesstill leak into observational
databases.
SPEAKER_01 (15:21):
He explicitly cites factors like health-seeking
behaviors, frailty trajectories,and access to care.
SPEAKER_00 (15:28):
We really need to define health-seeking behaviors
deeply here because it is theultimate spoiler of medical
statistics.
SPEAKER_01 (15:35):
Let's do it.
Let's look at the psychology ofthe patient.
The person who takes theinitiative to research a
preventative shingles vaccine,call their physician, navigate
their insurance.
SPEAKER_00 (15:44):
And voluntarily take an injection for a disease they
don't even have yet.
SPEAKER_01 (15:48):
Exactly.
That person operates with a highlevel of medical literacy and
personal agency.
SPEAKER_00 (15:53):
It's the healthy user bias.
That same patient isstatistically far more likely to
adhere to a Mediterranean dietor to maintain a consistent
cardiovascular exercise routine.
SPEAKER_01 (16:04):
And they aggressively manage their
cholesterol and blood pressure.
They are more likely to engagein cognitively demanding tasks,
and they generally possess asocioeconomic stability that
reduces chronic stress.
SPEAKER_00 (16:16):
Conversely, the patient who does not get the
vaccine might be on what Dr.
Cutler calls a frailtytrajectory.
SPEAKER_01 (16:22):
Meaning they might already be experiencing the
early subtle onset of physicalor cognitive decline, which
makes it just too difficult toschedule preventative care in
the first place.
SPEAKER_00 (16:31):
Or they simply lack the access to a reliable clinic.
SPEAKER_01 (16:34):
So the core debate emerges.
Are the vaccinated individualsaging slower and retaining their
cognition because the chemicalcomponents of the vaccine are
altering their brain chemistry?
SPEAKER_00 (16:45):
Or does the presence of a shingles vaccination in a
medical chart merely serve as areliable marker for a patient
who was already predisposed to along, healthy life due to a
hundred other daily choices?
SPEAKER_01 (16:58):
It is the ultimate chicken or the egg scenario.
Does the intervention cause thehealth, or does the healthy
person seek the intervention?
SPEAKER_00 (17:06):
But Dr.
Cutler takes this a step furtherin the text.
He introduces a fascinatingdichotomy about how the vaccine
actually functions.
SPEAKER_01 (17:14):
Yeah, this is great.
I'm quoting directly from thearticle here.
The two factors that come to mymind raising the possibility
that shingles vaccines may lowerdementia risk are the vaccine
itself and the avoidance of theshingles disease.
SPEAKER_00 (17:25):
This is a brilliant distillation of the
immunological mystery.
He is separating the activechemical intervention from the
passive biological outcome.
SPEAKER_01 (17:33):
Let's break down mechanism A first, the active
intervention.
In this scenario, the liquid inthe syringe, whether it's the
live virus in Zostavax or theadjuvant in Shingrix, enters the
bloodstream and actively changesthe environment of the brain.
SPEAKER_00 (17:47):
Perhaps it stimulates microglia, which are
the immune cells of the brain,to aggressively hunt down and
clear out amyloid beta plaquesbefore they can form the tangles
associated with Alzheimer'sdisease.
SPEAKER_01 (17:59):
That would be a direct pharmacological effect of
the vaccine.
SPEAKER_00 (18:02):
Right.
But mechanism B is entirelydifferent.
In mechanism B, the vaccine doesabsolutely nothing to the brain.
SPEAKER_01 (18:08):
Because in clear plaques, it doesn't alter brain
chemistry.
SPEAKER_00 (18:11):
All it does is successfully lock the varicella
zoster virus in the nerveganglion, completely preventing
a shingles outbreak.
SPEAKER_01 (18:19):
And why would simply avoiding the outbreak protect
the brain?
SPEAKER_00 (18:22):
Because a full-blown shingles infection is a massive
traumatic physiological event.
SPEAKER_01 (18:27):
Right.
When that virus travels down thenerve and erupts on the skin, it
causes a tremendous spike insystemic inflammation.
It floods the body withcytokines.
SPEAKER_00 (18:37):
And if you are 75 years old and your blood-brain
barrier is already slightlycompromised by age, that massive
wave of systemic viralinflammation could easily cross
into the brain.
SPEAKER_01 (18:47):
Which would accelerate neurodegeneration and
trigger the rapid onset ofdementia.
SPEAKER_00 (18:52):
Think of the vaccine as a highly effective seatbelt.
The physical fabric of theseatbelt does not actively
repair your car's engine, right?
SPEAKER_01 (19:00):
Right.
It doesn't make the car runsmoother.
SPEAKER_00 (19:02):
But wearing the seatbelt prevents you from
flying through the windshieldduring a catastrophic collision.
By entirely avoiding the traumaof the crash, the car and the
driver survive longer.
SPEAKER_01 (19:13):
I love that analogy.
It's like asking if wearing aseatbelt makes your car run
better, or if avoiding a massivecrash is what keeps your car
running better.
And if the cognitive benefit ofthe vaccine relies entirely on
mechanism B simply avoiding thecrash, then our earlier fears
about Shingrix versus Zostavacsare completely inverted.
SPEAKER_00 (19:33):
Exactly.
If the goal is purely to preventthe systemic inflammatory storm
of a viral reactivation, thenShingrix, with its 90% efficacy
rate, should theoretically be avastly superior shield for the
brain than the old 51% effectivevaccine.
SPEAKER_01 (19:47):
But again, we don't have the longitudinal data to
prove which mechanism is thetrue driver yet.
Is it the chemical compositionof the old vaccine or is it the
avoidance of the viral trauma?
SPEAKER_00 (19:57):
It is a phenomenal puzzle.
And just as we are wrestlingwith the mechanics of
neurodegeneration, the sourcematerial throws a second, even
more profound claim onto thetable.
SPEAKER_01 (20:08):
Oh man, here's where it gets really interesting.
We shift our focus from thepreservation of cognitive
function to the fundamentalalteration of the biological
aging process itself.
SPEAKER_00 (20:18):
The article highlights a January study
published in the Journal ofGerontology Series A.
SPEAKER_01 (20:23):
The researchers, including Dr.
John K.
Kenders, a research associateprofessor of gerontology,
utilized the U.S.
Health and Retirement Study.
They examined a massive cohortof over 3,800 participants who
were 70 years of age or older in2016.
SPEAKER_00 (20:38):
And they moved beyond diagnostic codes for
dementia.
They looked closely at theactual physiological and
molecular markers of cellularaging.
SPEAKER_01 (20:46):
They assessed seven distinct pillars of biological
age.
I want to list these out becauseit's intense: inflammation,
innate immunity, adaptiveimmunity, cardiovascular
hemodynamics, neurodegeneration,epigenetic aging, and
transcriptomic aging.
SPEAKER_00 (20:59):
And the findings were staggering.
SPEAKER_01 (21:01):
The individuals who had received a shingles vaccine
demonstrated a significantlylower composite biological aging
score.
They were, at a cellular level,younger than their chronological
AIDS would suggest.
SPEAKER_00 (21:13):
We really need to dissect these seven markers
because they map out the exactpathways where a virus and a
vaccine might be manipulatingour internal clocks.
SPEAKER_01 (21:22):
Let's do it.
The first three markers aredeeply intertwined with the
immune system (21:25):
inflammation, innate immunity, and adaptive
immunity.
Let's start with inflammation.
SPEAKER_00 (21:32):
Systemic inflammation is essentially the
bedrock of aging.
When we talk about measuringinflammation, we're usually
looking at biomarkers in theblood, like C reactive protein
or CRP or interleukin 6.
SPEAKER_01 (21:44):
High levels indicate the body is in a constant low
grade state of alarm.
SPEAKER_00 (21:48):
Yes.
And this leads directly into themeasurements of innate and
adaptive immunity.
The innate immune system is yourbroad immediate response.
Cells like macrophages andneutrophils that attack any
form.
Or an invader indiscriminately.
SPEAKER_01 (22:01):
And the adaptive system, like we discussed
earlier with T cells and Bcells, is the highly specialized
memory-driven response.
SPEAKER_00 (22:08):
Right.
As we age, both systems degrade.
The innate system often becomeshyperactive, contributing to
that chronic inflammation, whilethe adaptive system becomes
exhausted, losing its ability tofight off specific, novel
threats.
SPEAKER_01 (22:23):
So the vaccinated group showed better preservation
of these immune architectures.
That's huge.
The fourth marker they analyzedwas cardiovascular hemodynamics.
SPEAKER_00 (22:33):
This refers to the physical mechanics of blood
flow.
How stiff are the arteries, howresponsive is the endothelial
lining of the blood vessels.
SPEAKER_01 (22:41):
Because chronic viral infections and systemic
inflammation cause immense sheerstress on the vascular system,
don't they?
SPEAKER_00 (22:47):
They absolutely do.
If a vaccine reduces thatinflammatory burden, the blood
vessels retain their elasticitylonger, ensuring optimal blood
flow, not just to the heart, butto the microvasculature of the
brain.
SPEAKER_01 (22:58):
Aaron Powell, which bridges perfectly to the fifth
marker, neurodegeneration.
And this isn't just a cognitivetest, right?
SPEAKER_00 (23:03):
No, researchers can look at physical biomarkers like
neurofilament light chainproteins in the blood, which
only appear when structuraldamage is occurring to the
neurons themselves.
SPEAKER_01 (23:12):
Okay, but the final two markers are where the
concept of biological agingbecomes truly molecular,
epigenetic aging andtranscriptomic aging.
Can you translate this heavyjargon for us?
Let's plunge into the deep endof the cellular pool.
Epigenetics.
SPEAKER_00 (23:28):
Gladly.
We know our DNA is a fixedinstruction manual.
You are born with a specificsequence of genes, and barring a
mutation, that sequence does notchange.
SPEAKER_01 (23:37):
But how those genes are expressed changes
constantly.
SPEAKER_00 (23:40):
Exactly.
The primary mechanism ofepigenetic aging involves DNA
methylation.
Chemical tags, known as methylgroups, attach themselves to
specific sites on your DNA.
SPEAKER_01 (23:50):
And these tags act as volume knobs, turning the
expression of certain genes upor down.
SPEAKER_00 (23:55):
As we age, the placement of these methyl tags
becomes erratic.
Essential repair genes might getturned off, while inflammatory,
degrading genes get permanentlyturned on.
SPEAKER_01 (24:03):
And scientists use epigenetic clocks like the
Horvath clock to read thesemethylation patterns and
determine a person's truebiological age.
SPEAKER_00 (24:11):
Yes, and transcriptomic aging takes it a
step further down the assemblyline.
SPEAKER_01 (24:16):
Okay, so the DNA is the manual, but the RNA is the
messenger.
Transcriptomics is the study ofmessenger RNA, right?
SPEAKER_00 (24:22):
Correct.
It looks at how accurately thegenetic instructions are being
transcribed and carried to theribosomes to build proteins.
SPEAKER_01 (24:29):
And in an aging cell, transcription becomes
sloppy.
SPEAKER_00 (24:32):
Very sloppy.
The cell starts producingmisfolded proteins, or it stops
producing critical maintenanceenzymes altogether.
The cellular environmentbasically becomes cluttered with
biological junk.
SPEAKER_01 (24:43):
But according to this study, the shingles vaccine
was correlated with slowerepigenetic and transcriptomic
aging.
The vaccinated individuals hadcleaner DNA methylation patterns
and more accurate RNAtranscription.
SPEAKER_00 (24:55):
Which begs the question.
SPEAKER_01 (24:56):
Yeah, how is it physically possible that an
injection targeting a dormantchicken pox virus keeps the
cellular instruction manualrunning like a younger machine?
SPEAKER_00 (25:05):
Dr.
Young Key Kim offers a verycompelling hypothesis here,
centered around the concept ofbackground inflammation.
SPEAKER_01 (25:11):
Okay, let's bring our sleeper agent analogy back.
The varicilla virus is hiding inthe nerve ganglion.
It is being guarded by aging Tcells.
What if the virus isn'tperfectly dormant?
What if it's restless?
SPEAKER_00 (25:23):
In immunology, we call this subclinical
reactivation.
The virus is constantlyattempting to multiply.
It pushes against the weakened Tcell perimeter.
SPEAKER_01 (25:33):
And the immune system detects this minor breach
and mounts a small, localizedresponse to beat the virus back
into latency.
SPEAKER_00 (25:41):
Exactly.
You never develop a rash, younever feel neuropathic pain, you
have no idea this microscopicwar is happening.
SPEAKER_01 (25:47):
But the war generates heat.
SPEAKER_00 (25:48):
Yes.
The constant repetitive cycle ofsubclinical reactivation and
immune suppression creates asteady drip of inflammatory
cytokines into the bloodstream.
SPEAKER_01 (25:58):
This is the background inflammation Dr.
Kim refers to.
SPEAKER_00 (26:01):
It is like a stove burner left on a low simmer for
decades.
That simmering heat damages theendothelial lining of your blood
vessels.
It exhausts your adaptive immunecells.
SPEAKER_01 (26:10):
And critically, it disrupts the delicate epigenetic
machinery, causing the erraticDNA methylation that accelerates
biological aging.
SPEAKER_00 (26:18):
But by administering the shingles vaccine, you are
sending massive reinforcementsto the perimeter.
SPEAKER_01 (26:23):
You boost the T cell response so aggressively that
the virus is forced into a muchdeeper state of latency.
SPEAKER_00 (26:29):
The subclinical reactivations cease, the
microscopic war ends.
SPEAKER_01 (26:33):
The stove is turned off.
SPEAKER_00 (26:34):
And without that constant simmering background
inflammation, your epigenetictags stabilize, your RNA
transcription cleans up, yourcells are no longer aging under
the stress of a hidden chronicviral load.
SPEAKER_01 (26:47):
It is a breathtaking biological theory.
The idea that a single latentchildhood virus is quietly
acting as a chronometer, takingaway our biological youth, and
that a vaccine can simply pausethe clock.
SPEAKER_00 (27:00):
It is beautiful in its elegance.
But and there's always a but Dr.
Trin is waiting in the wings tobring us back to epidemiological
reality here, too.
SPEAKER_01 (27:08):
Right.
He explicitly labels thefindings in the biological aging
paper as hypothesis generating.
SPEAKER_00 (27:14):
Because he levels the exact same critique here
that Dr.
Cutler aimed at the dementiastudy.
Observational data, residualconfounding.
SPEAKER_01 (27:20):
Are the people in the U.S.
Health and Retirement Studyexhibiting youthful
transcriptomic profiles becausethey received the shingles
vaccine?
SPEAKER_00 (27:28):
Or did they receive the shingles vaccine because
they belong to a socioeconomicdemographic that affords them
low stress environments, highquality nutrition, and early
medical intervention?
SPEAKER_01 (27:37):
All of which profoundly influence DNA
methylation and systemicinflammation completely
independently of any vaccine.
SPEAKER_00 (27:45):
Right.
Even when biostatisticians buildcomplex models to mathematically
adjust for income, education,and observable health behaviors,
it is practically impossible toperfectly isolate the biological
effect of a single vaccine fromthe sprawling reality of a human
life.
SPEAKER_01 (28:00):
Which brings us to the ultimate question for you,
the listener.
We have analyzed incrediblyexciting, statistically
significant data from massivepopulation studies, data
suggesting that the shinglesvaccine might protect the brain
and slow the cellular agingclock.
SPEAKER_00 (28:15):
And we have also examined the rigorous structural
skepticism from physicians whowarn against conflating
correlation with causation,especially when dealing with
fundamentally different vaccinemechanics, like Zostavax versus
Shingrix.
SPEAKER_01 (28:30):
So we have incredibly exciting data weighed
against heavy medicalskepticism.
Where does that leave you whenyou visit your doctor tomorrow?
What is the actionable strategyhere?
SPEAKER_00 (28:40):
The strategy requires embracing what Dr.
Trin calls the bonus philosophy.
But first, we must adhere to theestablished medical guidelines
explicitly detailed in thesource material.
SPEAKER_01 (28:50):
Right, let's look at the current CDC guidelines,
which are clear and currentlyuninfluenced by the dementia or
aging data.
SPEAKER_00 (28:57):
The CDC recommends two doses of the shingles
vaccine for adults who are ages50 and older.
SPEAKER_01 (29:02):
Furthermore, they recommend it for adults 19 years
and older who are or will beimmunodeficient or
immunosuppressed due to diseaseor therapy.
SPEAKER_00 (29:10):
And those two doses are administered two to six
months apart.
If you meet these demographiccriteria, the medical consensus
is completely unified.
You should receive the vaccineto prevent the devastating
neuropathic pain andcomplications of a shingles
outbreak.
SPEAKER_01 (29:26):
But regarding the secondary benefits, Dr.
Trin states his advice topatients plainly.
He says, do it for shinglesprevention.
Any cognitive or aging benefitwould be a bonus if future
trials confirm it.
SPEAKER_00 (29:38):
It's the only rational approach.
You are purchasing theintervention to stop the virus.
If in 10 years randomizedcontrol trials prove that
shingrix also preserved yourepigenetic clock and shielded
your blood-brain barrier, youreap a massive dividend.
SPEAKER_01 (29:52):
But you cannot rely on a theoretical dividend as
your primary cognitive defensestrategy.
SPEAKER_00 (29:56):
Absolutely not.
Because we already possess ahighly effective proven arsenal
for dementia prevention.
SPEAKER_01 (30:03):
Yes.
Dr.
Cutler outlines 10 specificlifestyle adjustments in the
article.
People constantly search for apharmaceutical magic bullet to
save their brain while totallyignoring the difficult daily
maintenance that fundamentallyalters neurodegeneration.
SPEAKER_00 (30:17):
If we connect this to the bigger picture, we need
to dissect his list becausethese aren't just generic
platitudes, they are powerfulbiological levers.
SPEAKER_01 (30:25):
Let's begin with the cardiovascular foundation.
Dr.
Cutler lists controlling bloodpressure, keeping cholesterol in
check, avoiding tobacco use, andlimiting alcohol consumption.
SPEAKER_00 (30:36):
We discussed cardiovascular hemodynamics
earlier.
The brain is the mostmetabolically demanding organ in
the body.
It requires a massive,uninterrupted flow of oxygen and
nutrients through a delicatenetwork of microvessels.
SPEAKER_01 (30:51):
And chronic high blood pressure creates sheer
stress that damages theendothelial lining of these
vessels, leading to microbleedsand vascular dementia.
SPEAKER_00 (31:00):
Exactly.
High cholesterol drivesatherosclerosis, literally
choking off the cerebral bloodsupply over time.
SPEAKER_01 (31:06):
And tobacco introduces immense oxidative
stress and chemical toxinsdirectly into the bloodstream,
rapidly accelerating endothelialdysfunction.
SPEAKER_00 (31:14):
While alcohol is a direct neurotoxin that not only
damages neurons but severelydisrupts the architecture of
restorative sleep.
SPEAKER_01 (31:20):
This leads perfectly to his next points regular
physical exercise, eating ahealthy diet, preventing and
controlling diabetes, andmaintaining a healthy body
weight.
SPEAKER_00 (31:30):
These are the primary regulators of systemic
inflammation.
Adipose tissue body fat is notsimply inert storage, it is an
active endocrine organ thatsecretes inflammatory cytokines.
SPEAKER_01 (31:41):
So maintaining a healthy weight directly reduces
the simmering heat we discussedearlier.
SPEAKER_00 (31:46):
Yes.
And preventing diabetes preventsinsulin resistance in the brain,
a condition so closely linked toAlzheimer's that some
researchers refer to the diseaseas type 3 diabetes.
SPEAKER_01 (31:57):
And physical exercise does more than just
pump blood, right?
It triggers the release ofbrain-derived neurotrophic
factor, or BDNF.
SPEAKER_00 (32:04):
BDNF is essentially a fertilizer for the brain.
It stimulates neurogenesis, thecreation of new neurons,
particularly in the hippocampus,the region responsible for
memory and learning.
SPEAKER_01 (32:14):
The final two adjustments on Dr.
Cutler's list target theneurological architecture
directly, getting adequate sleepand avoiding social isolation.
SPEAKER_00 (32:21):
Sleep is not merely a period of inactivity, it is an
aggressive mechanical cleaningcycle.
SPEAKER_01 (32:26):
Oh, the glymphatic system.
I love this topic.
Deep sleep activates theglymphatic system.
The astrocytes, the supportcells in your brain, literally
shrink in size.
SPEAKER_00 (32:37):
Allowing cerebrospinal fluid to rush
through the brain tissue andwash away the toxic metabolic
waste that accumulates duringwaking hours.
SPEAKER_01 (32:44):
Including the amyloid beta proteins implicated
in dementia.
If you chronically restrictsleep, the trash just piles up.
SPEAKER_00 (32:51):
And avoiding social isolation addresses the
cognitive reserve hypothesis.
The human brain is an intenselysocial computational engine.
SPEAKER_01 (32:59):
Engaging in complex conversation, navigating
empathy, maintainingrelationships, it all requires
massive, continuousneuroplasticity.
SPEAKER_00 (33:08):
Isolation deprives the brain of its primary
stimulus, causing the synapticnetworks to atrophy from disuse.
SPEAKER_01 (33:14):
It is such a comprehensive, empowering list.
You do not need to wait for adecade of clinical trials to
turn down your systemicinflammation.
You do not need a vaccine tostimulate your lymphatic system
tonight.
SPEAKER_00 (33:25):
No, you don't.
A brisk walk, a tightlycontrolled blood sugar level, a
solid eight hours of sleep, anda meaningful conversation with a
friend are the most powerfulepigenetic regulators currently
available to you.
SPEAKER_01 (33:39):
Modern medicine doesn't rely on magic bullets.
As Dr.
Cutler notes, it would be aphenomenal advance if a simple
safe vaccine could eventually beadded to this protective
arsenal.
SPEAKER_00 (33:49):
But a medical intervention will only ever
complement, not replace, thefoundational physiology built by
daily habits.
SPEAKER_01 (33:56):
So what does this all mean?
We have covered a tremendousamount of ground today.
We started by examining theterrifying latency of the
Varicella's Oscar virus, asleeper agent hiding in the
sensory ganglia, waiting for theimmune system to falter.
SPEAKER_00 (34:09):
We explored how the brilliant regression
discontinuity design of theStanford study revealed a 20%
drop in dementia risk.
SPEAKER_01 (34:16):
And how researchers are desperately trying to
unravel the biologicalmechanisms driving that drop.
We waded through the criticalskepticism of the medical
community, unpacking theprofound differences between
live-attenuated and recombinantvaccines.
SPEAKER_00 (34:28):
And acknowledging the inescapable shadow of
residual confounding inobservational data.
SPEAKER_01 (34:34):
We explored the beautiful theory that
suppressing subclinical viralreactivation might turn off the
chronic background inflammationthat accelerates our epigenetic
and transcriptomic aging clocks.
SPEAKER_00 (34:45):
It really highlights a thrilling evolution in medical
science.
We're moving away from viewingthe body as a collection of
isolated systems.
SPEAKER_01 (34:53):
We're beginning to understand that the immune
response to a nerve ganglioninfection in your spine is
inextricably linked to themolecular aging of your
cardiovascular system and thepreservation of your cerebral
cortex.
The web is entirely connected.
SPEAKER_00 (35:08):
But true health literacy requires patience.
Knowledge is only valuable whenapplied with critical thinking.
The headlines offer immediate,miraculous answers.
The science demands rigorouslongitudinal clinical trials.
SPEAKER_01 (35:20):
To differentiate the active effects of an adjuvant
from the passive benefits ofavoiding a viral trauma, you
must use the data to inform yourunderstanding, not to replace
your foundational healthstrategies.
SPEAKER_00 (35:31):
Exactly.
We must be patient for thescience to catch up to the
headlines.
SPEAKER_01 (35:35):
But before we sign off, I want to leave you, the
listener, with one final deeplyprovocative thought that stems
directly from everything we'vediscussed today.
SPEAKER_00 (35:44):
Proceed.
SPEAKER_01 (35:44):
We have spent all this time dissecting the
profound systemic damage causedby just one virus, the Vericella
zoster virus.
A virus most of us acquired inchildhood that we assumed we
defeated, but which quietly setup latency in our nervous
system, subtly exhausting our Tcells and dripping inflammatory
cytokines into our bloodstreamfor decades.
(36:06):
If preventing the localizedreactivation of just this single
dormant virus can theoreticallyalter our neurodegeneration and
drastically lower our compositebiological aging scores, how
many other seemingly harmlesslatent viruses are quietly
sleeping in our cellulararchitecture right now?
SPEAKER_00 (36:23):
Like Epstein-Barr or Cytomegalovirus.
SPEAKER_01 (36:26):
Exactly.
Are they generating backgroundinflammation and silently
accelerating our biologicalclocks without us ever realizing
the war is happening?
SPEAKER_00 (36:33):
That is the frontier of immunology, and it is a
question that will redefine howwe approach aging in the coming
decades.
SPEAKER_01 (36:38):
Something to mull over while you activate your
lymphatic system tonight.
Thank you for joining us on thisdeep dive into the complex,
fiercely debated, and incrediblyhopeful edge of medical science.
We'll catch you next time.
Popular Podcasts
Joy 101 with Hoda Kotb
Joy is essential. And it's also elusive. You can't order it, borrow it, or simply hope it into life. But now, there's a new and exciting way to start your journey toward a more joyful existence: The Joy 101 Podcast with Hoda! Best known for her Emmy-winning work and co-anchoring Today, Hoda Kotb infuses her authenticity, curiosity, and warmth into conversations with the world’s most fascinating people. Entertainment legends, sport icons, wellness experts, and everyday folks will share how they find, allow, and experience joy. Hoda will offer her own tips and takes on seeking a more balanced, harmonious life. If you're craving inspiration, support, and useful tools to maximize your joy, tune in to these candid, uplifting, and moving on-air chats. Joy after a breakup, joy as an empty-nester, joy after loss, joy as a caretaker — Hoda's new podcast will speak to you. Joy 101 with Hoda Kotb, an iHeartPodcast.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com